Antares Therapeutics has launched with $177 million in series A financing and a staff already at full speed, according to CEO Adam Friedman. The company is a spin-off of Scorpion Therapeutics ...

Antares Therapeutics spun off of Scorpion Therapeutics, a clinical-stage biotech that Eli Lilly acquired earlier this year. Like Scorpion, Antares is developing small molecules that go after ...

Eli Lilly and Co.’s end last year to its PI3Kα inhibitor program didn’t mean the pharma player was giving up on the target – far from it, as signaled by the potential $2.5 billion deal signed recently ...

What potential value does the Scorpion acquisition bring to Relay? The $2.5 billion acquisition of Scorpion Therapeutics could prove to be a transformative move for Relay.

Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.

Under the terms of the deal, Scorpion shareholders could receive up to $2.5 billion in cash in upfront and subsequent payments dependent on the achievement of certain regulatory and sales metrics.

Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments.

Scorpion's current pipeline, led by STX-478, our mutant-selective PI3Ka program, consists of three internally discovered clinical product candidates and multiple discovery-stage programs.

Scorpion's current pipeline, led by STX-478, our mutant-selective PI3Kα program, consists of three internally discovered clinical product candidates and multiple discovery-stage programs.